Windlas Biotech
Windlas Biotech Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Windlas Biotech Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Windlas Biotech Ltd trades at a P/E of 25.50× and P/B of 3.01×.
Valuation
Profitability
Growth
Financial Health
Windlas Biotech Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Windlas Biotech Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Windlas Biotech Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Windlas Biotech Ltd, switchable between annual and quarterly views, consolidated or standalone.
Windlas Biotech Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,722.27 Cr and reported EPS of ₹31.50.
| Period | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue from Operations | 466 | 513 | 631 | 760 | 904 |
| Other Income | 7 | 10 | 13 | 18 | 18 |
| Total Income | 473 | 523 | 644 | 778 | 922 |
| Cost of Goods Sold (COGS) | 303 | 325 | 396 | 472 | 557 |
| Gross Profit | 163 | 188 | 235 | 288 | 347 |
| +Operating Expenses | 111 | 127 | 157 | 194 | 242 |
| EBITDA | 52 | 60 | 78 | 94 | 105 |
| +Non-Operating Expenses | 14 | 13 | 15 | 32 | 36 |
| Profit Before Tax (PBT) | 46 | 57 | 77 | 80 | 87 |
| +Tax Expense | 7 | 14 | 19 | 19 | 21 |
| Profit After Tax (PAT) | 38 | 43 | 58 | 61 | 66 |
| Earnings Per Share (EPS) | 17.39 | 20.35 | 27.98 | 29.10 | 31.49 |
| Diluted Shares Outstanding (Nos.) | 2 | 2 | 2 | 2 | 2 |
| +Additional Disclosures | 730 | 791 | 963 | 1,169 | 1,392 |
| Sales Growth % | — | 10.12 | 22.97 | 20.43 | 18.98 |
| YoY Sales Growth % | — | 10.12 | 22.97 | 20.43 | 18.98 |
| Material Cost % | 66 | -0 | 0 | 0 | 1 |
| Employee Cost % | 14 | 14 | 14 | 16 | 17 |
| Other Cost % | 10 | 11 | 11 | 9 | 10 |
| OPM % | 11 | 12 | 12 | 12 | 12 |
| Tax % | 16 | 25 | 25 | 24 | 24 |
| Profit Growth % | — | 11.91 | 36.51 | 4.82 | 8.95 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 40 | 48 | 65 | 66 | 74 |
Windlas Biotech segment analysis: revenue and profit mix.
Disclosed business segments at Windlas Biotech with their share of revenue and profit, switchable between consolidated and standalone reporting.
Windlas Biotech discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Windlas Biotech Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Windlas Biotech Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Windlas Biotech Ltd's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Robust quarterly sales (20.00%) and profit (31.00%) growth demonstrate strong momentum.
Very low debt-to-equity ratio (0.06) ensures strong financial stability.
High promoter holding (62%) signals strong management confidence.
P/E ratio (30.70) below sector average (33.87) suggests competitive valuation.
Impressive 5-year EPS (31.17%) and revenue (18.24%) growth indicates sustained performance.
What can break it.
Modest Return on Equity (12.80%) suggests room for efficiency improvement.
ROCE (17.00%) lags peers like Sun Pharma, indicating efficiency gaps.
Declining FII holding (3.21% to 1.11%) indicates reduced foreign investor interest.
Recent stock volatility and trading below 52-week high (1198) observed.
Low dividend yield (0.45%) may not attract income-focused investors.
What would change my mind.
Trim if P/E re-rates above 33. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Windlas Biotech Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Windlas Biotech Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Windlas Biotech Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Windlas Biotech Ltd — derived from the live tape, not yesterday's close.
Windlas Biotech Ltd last traded at ₹816 with an intraday range of ₹803.05–₹830 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹816.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 883.55 | +67.55 | +8.28% |
| R3 | 856.60 | +40.60 | +4.98% |
| R2 | 843.30 | +27.30 | +3.35% |
| R1 | 829.65 | +13.65 | +1.67% |
| PIVOT | 816.35 | 0.35 | 0.04% |
| CURRENT | 816.00 | — | — |
| S1 | 748.80 | -67.20 | -8.24% |
| S2 | 775.75 | -40.25 | -4.93% |
| S3 | 789.40 | -26.60 | -3.26% |
| S4 | 802.70 | -13.30 | -1.63% |
WINDLAS is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: 803.05 ~ 818.8
Trading Inside opening range
Windlas Biotech Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Windlas Biotech Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Windlas Biotech Ltd stood at 62.2% of traded volume, against a 20-day average of 60.2%.
Windlas Biotech announcements: results, concalls, ratings, M&A.
Filings Windlas Biotech sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Windlas Biotech files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 73 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Windlas Biotech Limited has informed the Exchange about Transcript
Analysts/Institutional Investor Meet/Con. Call Updates
Windlas Biotech Limited has informed the Exchange about Link of Recording
Disclosure under SEBI Takeover Regulations
Manoj Kumar Windlass has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Copy of Newspaper Publication
Windlas Biotech Limited has informed the Exchange about Copy of Newspaper Publication for Post Buyback Public Announcement
Copy of Newspaper Publication
Windlas Biotech Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
Windlas Biotech dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Windlas Biotech has declared, sequenced by announce and record date.
Windlas Biotech corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Windlas Biotech Ltd: business, sector, key facts.
What Windlas Biotech Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Windlas Biotech Ltd operates in the Healthcare, listed as NSE: WINDLAS, BSE: 543329.
Windlas Biotech Limited is a prominent contract development and manufacturing organization (CDMO) operating in the pharmaceutical industry, both domestically within India and on a global scale. Their core business revolves around providing comprehensive CDMO solutions to other pharmaceutical companies, encompassing the entire lifecycle from initial product development and securing necessary licenses to the large-scale commercial manufacturing of diverse pharmaceutical products.
The company specializes in the production of complex drugs and various dosage forms, demonstrating a high level of technical expertise and manufacturing capabilities. This expertise extends to a wide range of pharmaceutical products including tablets, capsules, pouches, sachets, and liquid bottles. Their manufacturing capabilities are not limited to simple formulations, they also handle more intricate formulations such as fixed dosage combinations, fixed dosage plus modified release combinations, customized generics, and specialized formats like chewable or dispersible tablets, and plain oral solid dosage forms.
Beyond its CDMO services, Windlas Biotech also has a significant presence in the manufacturing and trading of generic pharmaceutical products. This further diversifies their revenue streams and establishes them as a key player within the broader Indian and international pharmaceutical market. Their portfolio of generic products caters to a wide range of therapeutic needs, solidifying their position as a reliable supplier of affordable and accessible medications.
In addition to traditional pharmaceuticals, Windlas Biotech also engages in the production of nutraceutical supplement products, highlighting their adaptability and expansion into related health and wellness markets. This diversification strategy allows the company to tap into growing consumer demand for health-enhancing supplements, further broadening their product range and market reach. This strategic diversification demonstrates their commitment to growth and innovation within the broader healthcare industry.
Established in 2001 and headquartered in Gurugram, India, Windlas Biotech Limited has built a strong reputation based on its expertise in complex pharmaceutical manufacturing, comprehensive CDMO services, and diverse product portfolio. This combination of factors positions the company for continued success and growth in the dynamic and ever-evolving global pharmaceutical landscape.
Questions investors ask about Windlas Biotech Ltd (WINDLAS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Windlas Biotech Ltd (WINDLAS)?
The current share price of Windlas Biotech Ltd (WINDLAS) is ₹816. Today, the stock has gained by ₹8.35 (1.03%), trading in a range of ₹803.05 to ₹830. The stock opened at ₹807.65 with a trading volume of 44,783 shares.
02Is Windlas Biotech Ltd stock a good investment for long-term?
Windlas Biotech Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,722.27 crores, P/E ratio of 25.50, ROE of 12.20%, and ROCE of 15.90%. The dividend yield stands at 0.75%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Windlas Biotech Ltd stock?
The 52-week high price of Windlas Biotech Ltd (WINDLAS) is ₹1,097.9, while the 52-week low is ₹697.4. Currently trading at ₹816, the stock is 29.6% away from its 52-week low and 25.7% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Windlas Biotech Ltd stock at the current price?
Whether to buy Windlas Biotech Ltd stock at ₹816 depends on multiple factors. The stock is currently trading with a P/E ratio of 25.50 and P/B ratio of 3.01. Today's performance shows a gain of 1.03%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Windlas Biotech Ltd and when is the next dividend?
Windlas Biotech Ltd offers a dividend yield of 0.75%, which means for every ₹100 invested at the current price of ₹816, you can expect to receive approximately ₹0.75 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Windlas Biotech Ltd?
Windlas Biotech Ltd's key financial metrics include: P/E Ratio: 25.50, P/B Ratio: 3.01, ROE: 12.20%, ROCE: 15.90%, Dividend Yield: 0.75%, EPS: ₹31.50, Book Value: ₹275, and Debt-to-Equity: 0.06. The company's market cap stands at ₹1,722.27 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Windlas Biotech Ltd stock performing today in the market?
Windlas Biotech Ltd stock opened at ₹807.65 and is currently trading at ₹816, showing a gain of ₹8.35 (1.03%). The intraday high is ₹830 and low is ₹803.05. The trading volume stands at 44,783 shares, indicating moderate market participation today.
08What is the P/E ratio of Windlas Biotech Ltd and what does it indicate?
Windlas Biotech Ltd has a Price-to-Earnings (P/E) ratio of 25.50, which means investors are willing to pay ₹25.50 for every ₹1 of earnings. With an EPS of ₹31.50, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Windlas Biotech Ltd (WINDLAS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy